The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients

References

• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542. doi: 10.1182/blood-2002-02-0492
   PubMed Web of Science ®Google Scholar
• Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82(4):1110–1119.
   PubMed Web of Science ®Google Scholar
• Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65(7):1143–1152. doi: 10.1016/0092-8674(91)90010-V
   PubMed Web of Science ®Google Scholar
• Kuczynski WI, Ratajczak MZ. STK-1 receptor gene is expressed in various human non-hematopoietic tumor cell lines--RT-PCR directed analysis of STK-1 mRNA expression. Preliminary report. Acta Haematol Pol. 1994;25(1):43–46.
   PubMedGoogle Scholar
• McKenna HJ. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr Opin Hematol. 2001;8(3):149–154. doi: 10.1097/00062752-200105000-00004
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood. 1994;83(10):2795–2801.
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75(6):1157–1167. doi: 10.1016/0092-8674(93)90325-K
   PubMed Web of Science ®Google Scholar
• Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368(6472):643–648. doi: 10.1038/368643a0
   PubMed Web of Science ®Google Scholar
• Lyman SD. Biology of flt3 ligand and receptor. Int J Hematol. 1995;62(2):63–73. doi: 10.1016/0925-5710(95)00389-A
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192(5):719–728. doi: 10.1084/jem.192.5.719
   PubMed Web of Science ®Google Scholar
• Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996;10(4):588–599.
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–1918.
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111(1):190–195. doi: 10.1046/j.1365-2141.2000.02317.x
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759. doi: 10.1182/blood.V98.6.1752
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335. doi: 10.1182/blood.V99.12.4326
   PubMed Web of Science ®Google Scholar
• Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11(9):1442–1446. doi: 10.1038/sj.leu.2400770
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983–988. doi: 10.1046/j.1365-2141.2001.02850.x
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–2439. doi: 10.1182/blood.V97.8.2434
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654–3661. doi: 10.1182/blood-2006-03-009233
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Ohno R, Ueda R, et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21(16):2555–2563. doi: 10.1038/sj.onc.1205332
   PubMed Web of Science ®Google Scholar
• Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 d835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2007;111(3):1552–1559. doi: 10.1182/blood-2007-08-107946
   PubMed Web of Science ®Google Scholar
• Annesley CE, Brown P. The biology and targeting of FLT3 in pediatric leukemia. Front Oncol. 2014;4:1663. doi: 10.3389/fonc.2014.00263
   Google Scholar
• Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97(1):89–94. doi: 10.1182/blood.V97.1.89
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee GD, Park J, et al. Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. Blood Cancer J. 2015;5:e336. doi: 10.1038/bcj.2015.61
   PubMed Web of Science ®Google Scholar
• Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2017;129(5):565–571. doi: 10.1182/blood-2016-09-693648
   PubMed Web of Science ®Google Scholar
• Wang L, Lin D, Zhang X, et al. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res. 2005;29(12):1393–1398. doi: 10.1016/j.leukres.2005.05.013
   PubMed Web of Science ®Google Scholar
• Andersson A, Johansson B, Lassen C, et al. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol. 2004;72(5):307–313. doi: 10.1111/j.1600-0609.2004.00225.x
   PubMed Web of Science ®Google Scholar
• Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88(1):19–24.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang L, Huang L, et al. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leuk Res. 2012;36(2):186–191. doi: 10.1016/j.leukres.2011.08.014
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19(8):1345–1349. doi: 10.1038/sj.leu.2403838
   PubMed Web of Science ®Google Scholar
• Schiller GJ. Evolving treatment strategies in patients with high-risk acute myeloid leukemia. Leuk Lymphoma. 2014;55(11):2438–2448. doi: 10.3109/10428194.2014.881479
   PubMed Web of Science ®Google Scholar
• Lin PH, Lin CC, Yang HI, et al. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res. 2013;37(3):287–292. doi: 10.1016/j.leukres.2012.10.005
   PubMed Web of Science ®Google Scholar
• DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011;17(9):1404–1409. doi: 10.1016/j.bbmt.2011.02.003
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: The role for FLT3 tyrosine kinase inhibitors post-transplantation. Biol Blood Marrow Transplant. 2016;22(6):982–990. doi: 10.1016/j.bbmt.2016.01.013
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–3665. doi: 10.1182/blood-2005-03-1323
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184–198. doi: 10.1093/jnci/djm328
   PubMed Web of Science ®Google Scholar